Background: Idiopathic inflammatory myopathies can be classified by clinicopathological phenotype into four major groups: overlap myositis (OM), dermatomyositis (DM), immune mediated necrotising myositis (IMMNM) and inclusion body myositis (IBM). The different phenotypes associate with distinct MSA specificities although a variable percentage within each group are seronegative and the majority of IBM patients are seronegative 1 . No commercial assay for the IBM associated specificity, cN1A, is available. In NZ testing for MSA is restricted to two laboratories: Waikato Hospital (WHL) and Canterbury Health Laboratories (CHL). Both laboratories use the commercial Euroimmun Euroline assay. In addition CHL has developed an ELISA for anti HMGCR autoantibodies and receives referrals from throughout NZ.
Objectives: To define the incidence and specificities of MSA in serum samples referred for testing in New Zealand. Methods: For the period 3 November 2015 to 2 November 2016 each laboratory information system (LIS) was interrogated for requests for MSA. For the purposes of this report positive results were grouped into the specificities associated with each of the defined clinicopathological phenotypes. DM: Mi2, Tif-γ, MDA 5 NXP2 SAE1 OM: Ku, PM-Scl-100, PL75, Jo1, PL-7, PL-12, EJ, OJ IMMNM: HMGCR, SRP Results: Of screened sera (n=793, CHL=622, WHL=171) 11% were positive for MSA (88/793). Positive sera where distributed amongst three clinicopathological associated autoantibody specificities: DM 23% OM 50%,IMMNM 27%. The most common serum specificities were HMGCR (n=24) and Jo-1 (n=13). No serum with specificities to SRP or OJ was detected. 22/24 sera positive for anti HMGCR had an elevated CPK concentration (CPK>2500u/l in 21/24 and CPK=544 in 1/24, reference range =66-220). Conclusions: In New Zealand 11% of sera referred for MSA testing were positive. As a group the most common specificities were those associated with OM while the most common antigen specificity was to HMGCR. Anti-HMGCR antibodies were almost invariably associated with major elevations in serum CPK. Background: Systemic sclerosis (SSc) is an autoimmune rheumatic disease with unknown etiology that characterized fibrosis and vascular endotelial damage with obliteration of the microvasculature caused from exaggerated syntesis of collagen and extracellular matrix deposition in skin and internal organs. Pentraxin 3 (PTX3) accepted as a vascular inflammatory marker which secreted in early stage of endothelial dysfunction. Objectives: In this study, we aimed to investigate plasma PTX3 and serum complement C1q levels and their relations with cytokines and pulmonary arterial pressure in SSc. Methods: Fifty nine patients diagnosed SSc and 28 subjects without inflammatory rheumatic disease recruited to the study. Plasma PTX3, and serum TNF-α, IL-1β, IL-4, IL-10, INF-γ, TGF-β and complement C1q measured in both groups. Clinical findings and pulmonary arterial pressure of the SSc patients assessed. Results: Ages of fifty nine with SSc (54 female and 5 male) and 28 control subjects (23 female and 5 male) were 49,47±12.74 and 43,07±13,71 respectively. PTX3, IL-1β and IL-4 levels found decreased in SSc patients. There were no differentiations between limited and diffuse cutaneous SSc subgroups in terms of PTX3, cytikines and C1q levels. Plasma PTX3 and serum IL-1β concentrations found decreased only limited cutaneous SSc subgroup comparing controls. According to the immunosupressive drugs use; PTX3 levels found decreased in using group and TNF-α ve IL-1β levels found decreased in not using group comparing controls. Significant positive association found between PTX3 and C1q and all cytokines except TGF-β. Conclusions: PTX3 suggested to be used in the pathogenesis and assessment of disease treatment efficacy of SSc, because of found decreased in SSc patients especially in limited cutaneous and immunosupressive drugs using subgroups. Associations between C1q, and PTX3 and pulmonary artey pressure highlighted possible roles of both parameters in development of pulmonary hypertension. It is possible to develop preventive treatment strategies with better understanding of these associations. Advanced studies should be carried out for clarifying this condition. 
